Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer

CONCLUSION: In this large cohort with long-term follow-up and trial-level quality assurance, models based on standard clinicopathologic variables had limitations in accurately estimating prognosis. The proportional benefit of ADT use was consistent, but the absolute magnitude of benefit varied greatly by predicted baseline risk of DM. Incorporation of genomic prognostic information into risk stratification to better estimate absolute ADT benefit are needed and ongoing (NCT04513717).PMID:34700633 | DOI:10.1016/j.ijrobp.2021.07.189

Source: Ann Oncol - October 27, 2021 Category: Cancer & Oncology Authors: R T Dess Y Sun M Bolla A Zapatero S Malone A U Kishan S Roy W C Jackson C A F Lawton O Sartor P L Nguyen J M Michalski T M Pisansky M Roach H M Sandler M Schipper F Y Feng D E Spratt Source Type: research